GRAIL Inc. (GRAL) Q2 2024 Earnings Call Transcript
GRAIL Inc. (NASDAQ:GRAL ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Bob Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Conference Call Participants Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Operator Good day, ladies and gentlemen, and welcome to the GRAIL Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
Grail to cut jobs, planned hires for 2024 by about 30%
Cancer test maker Grail said on Tuesday it would reduce existing headcount and planned hires for 2024 by about 30%, as part of its restructuring program.
3 Top Cancer Treatment Stocks to Buy Now
Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.
3 Spinoff Stocks You Should Buy Now: July 2024
Stock spinoffs remain popular with companies wanting to unlock shareholder value. By creating spinoff stocks that will trade independently on the market, corporations believe they can narrow their focus to core operations while the newly public company doesn't get lost in the shuffle of its parent's larger objectives.
